Purchase this article with an account.
Q. Gao, S. Mou, J. Ge, C.-H. To; A New Strategy to Replace the Natural Vitreous by a Novel Capsule-Like Artificial Vitreous Body With Pressure-Control Valve. Invest. Ophthalmol. Vis. Sci. 2007;48(13):5753.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
The current vitreous substitutes such as silicone oil, heavy silicone oil and polymeric gels that are directly injected into vitreous cavity frequently cause severe intraocular complications. There is a very urgent need to find a more suitable artificial vitreous substitute for Pars Plana Vitrectomy (PPV) surgery.
We have adopted a non-traditional method and devised a novel capsule-like artificial vitreous using tailor-made modified silicone rubber elastomer based on physiological parameters of rabbit's vitreous body. The novel devices were then implanted into rabbit's vitreous cavity after PPV and followed clinically by ophthalmoscopy, fundus photography and tonometry during an 8-week treatment period. B-scan ultrasonography, electroretinagram (ERG) and histological studies by light microscopy were also performed at the end of 8 weeks.
The novel artificial vitreous body consists of a thin vitreous-like capsule with a silicone tube-valve system. The capsule can be folded and implanted into vitreous cavity through 1.5mm scleal incision. Physiological balanced solution (PBS) was then injected into capsule and inflated to support retina and control intraocular pressure (IOP) through the tube-valve system subsequently fixed under the conjunctiva. Experiments using rabbits showed that the novel vitreous body could effectively support the retina and apparently induced no significant changes in ophthalmoscopic findings, IOP and ocular damages during an 8-week time.
This research approach may provide a new research strategy in the vitreous replacement technology. The novel artificial vitreous body implant can effectively support retina, control IOP and has good biocompatibility. It may be a good alternative to injecting artificial vitreous although it needs to be improved and proved in proliferative vitreoretinopathy.
This PDF is available to Subscribers Only